Xcout IntelMESOBLAST LTD
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Subscribe to see MESOBLAST LTD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MESOBLAST LTD at a glance
MESOBLAST LTD is a regenerative medicine company headquartered in Melbourne, Australia. It is publicly listed (MESO) with a market capitalisation of $1.8B. Xcout tracks 20 named people at MESOBLAST LTD, including Paul J. Simmons (Scientific Advisor to the Chief Executive Officer).
MESOBLAST LTD leadership
- Paul J. SimmonsScientific Advisor to the Chief Executive Officer
- James Michael O'BrienChief Financial Officer
- Eric A. RoseChief Medical Officer & Executive Director
- Marcelo SantoroChief Commercial Officer
- Silviu Itescu FACP FACRA FRACP MBBSFounder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director
- Fiona SeeSenior Vice President & Head of Translational Research
14 more named people on record for MESOBLAST LTD, with roles, board committees and tenure — see the full roster →
Get MESOBLAST LTD's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MESOBLAST LTD in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access